Physician profile
Robert Edward Hunt
NPI 1376513853
$407.47
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $394 · 2022: $13.89.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $122.27 | 2019 | |
| Novartis Pharmaceuticals Corporation | $89.84 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $84.88 | 2019 | |
| Cardiofocus, INC. | $56.59 | 2019 | |
| Angiodynamics, INC. | $21.15 | 2019 | |
| Astellas Pharma US INC | $18.85 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.89 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.